Systemic antifungal prescribing in neonates and children: Outcomes from the antibiotic resistance and prescribing in european children (arpec) study

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 782-789

  Lestner, J M ^a   Versporten, A ^b   Doerholt, K ^a   Warris, A ^c   Roilides, E ^d   Sharland, M ^a   Bielicki, J ^a   Goossens, H ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; DEOXYCHOLIC ACID; DRUG COMBINATION;

ADOLESCENT; ADULT; ARTICLE; CARDIAC INFECTION; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG USE; EDUCATION PROGRAM; FEBRILE NEUTROPENIA; HOSPITAL PATIENT; HOSPITALIZED CHILD; HOSPITALIZED INFANT; HUMAN; INFANT; INFECTION; INVASIVE CANDIDIASIS; LOW BIRTH WEIGHT; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEB BROWSER; CLINICAL TRIAL; DRUG COMBINATION; HOSPITAL; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FLUCONAZOLE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN;

EID: 84921907965     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04109-14     Document Type: Article

References (47)

1. Shane AL, Stoll BJ. 2014. Neonatal sepsis: progress towards improved outcomes. J Infect 68(Suppl 1):S24 -S32. http://dx.doi.org/10.1016/j.jinf .2013.09.011.
2. Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. 2007. Outcomes attributable to neonatal candidiasis. Clin Infect Dis 44:1187-1193. http://dx.doi.org/10.1086/513196.
3. Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T. 2012. Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care 2:6. http://dx.doi.org/10.1186/2110-5820-2-6.
4. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091-1100. http://dx.doi.org/10.1086/651263.
5. Versporten A, Sharland M, Bielicki J, Drapier N, Vankerckhoven V, Goossens H, ARPEC Project Group Members. 2013. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis J 32:e242-e253. http://dx.doi.org/10.1097 /INF.0b013e318286c612.
6. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H, ESAC-3 Hospital Care Subproject Group. 2011. Identification of targets for quality improvement in antimicrobial prescribing: the Web-based ESAC Point Prevalence Survey 2009. J Antimicrob Chemother 66:443-449. http://dx.doi.org/10.1093/jac/dkq430.
7. BAPM. 2001. British Association of Perinatal Medicine standards for hospitals providing neonatal intensive and high dependency care (second edition). British Association of Perinatal Medicine, London, United Kingdom. http://www.bapm.org/publications/documents/guidelines /hosp-standards.pdf.
8. R Development Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
9. Stata Corp. 2007. Stata statistical software: release 10. StataCorp, College Station, TX.
10. WHO. 2013. Anatomical Therapeutic Chemical (ATC) classification system: guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway.
11. United Nations. 2011. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. United Nations, New York, NY. http://unstats.un.org/unsd /methods/m49/m49regin.htm.
12. rd ed. Oxford University Press, Oxford, United Kingdom.
13. Pickering LK, Baker, Kimberlin DW, Long SS (ed). 2012. Red book 2012: 2012 report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL.
14. Electronic Medicines Compendium. 2013 Fluconazole 50mg capsules: summary of product characteristics. Electronic Medicines Compendium, Surrey, United Kingdom. http://www.medicines.org.uk/emc/medicine /25882.
15. EMA. 2014. (Voriconazole) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http://www.ema .europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/002669/WC500144015.pdf.
16. EMA. 2014. (Caspofungin) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http://www.ema .europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000379/WC500021033.pdf.
17. MHRA. 2013. (Itraconazole) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil /con1411711063531.pdf.
18. EMA. 2013. (Posaconazole) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http://www.ema .europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/000610/WC500037784.pdf.
19. MHRA. 2014. (Fungizone) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil /con1404458209656.pdf.
20. MHRA. 2014. (AmBisome) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/c on1410502129659.pdf.
21. MHRA. 2014. (Abelcet) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
22. EMA. 2014. (Mycamine) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http://www.ema .europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/000734/WC500031075.pdf.
23. McPhillips HA, Stille CJ, Smith D, Hecht J, Pearson J, Stull J, Debellis K, Andrade S, Miller M, Kaushal R, Gurwitz J, Davis RL. 2005. Potential medication dosing errors in outpatient pediatrics. J Pediatr 147:761-767. http://dx.doi.org/10.1016/j.jpeds.2005.07.043.
24. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID∗guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18(Suppl 7):S38 -S52. http://dx.doi.org/10.1111/1469-0691 .12040.
25. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T, Fourth European Conference on Infections in Leukaemia, Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EMBT-IDWP), Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG), International Immunocompromised Host Society (ICHS), European Leukaemia Net (ELN). 2014. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327-e340. http://dx.doi.org/10.1016/S1470-2045(14)70017-8.
26. Saxena S, Ismael Z, Murray ML, Barker C, Wong IC, Sharland M, Long PF. 2014. Oral penicillin prescribing for children in the UK: a comparison with BNF for children age-band recommendations. Br J Gen Pract 64: e217-e222. http://dx.doi.org/10.3399/bjgp14X677842.
27. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, Lyall EGH, Gibb DM, Collaborative HIV Paediatric Study Steering Committee. 2006. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 332:1183-1187. http://dx .doi.org/10.1136/bmj.332.7551.1183.
28. Benjamin DK, Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ. 2006. Safety and pharmacokinetics of intravenous anidulafungin in children with neutro-penia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50:632-638. http://dx.doi.org/10.1128/AAC.50.2.632-638.2006.
29. Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK, Jr. 2010. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 54:2633-2637. http://dx.doi.org/10.1128/AAC.01679-09.
30. Karlsson MO, Lutsar I, Milligan PA. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935-944. http://dx.doi.org/10.1128 /AAC.00751-08.
31. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 49:4536 - 4545. http://dx.doi.org/10.1128/AAC.49.11.4536 -4545.2005.
32. Barker CI, Germovsek E, Hoare RL, Lestner JM, Lewis J, Standing JF. 2014. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Adv Drug Deliv Rev 73:127-139. http://dx.doi.org/10.1016/j.addr.2014.01.002.
33. Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, Caselli D, Caviglia I, Parodi S, Rondelli R, Cornelli PE, Mura R, Santoro N, Russo G, De Santis R, Buffardi S, Viscoli C, Haupt R, Rossi MR. 2006. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 25:634-639. http://dx.doi .org/10.1097/01.inf.0000220256.69385.2e.
34. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. 2010. Epidemiology of paediatric invasive fungal infections and a casecontrol study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 149:263-272. http://dx.doi.org/10.1111/j.1365-2141 .2009.08072.x.
35. Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Palazzi DL, Castagnola E, Halasa N, Velegraki A, Dvorak CC, Charkabarti A, Sung L, Danziger-Isakov L, Lachenauer C, Arrieta A, Knapp K, Abzug MJ, Ziebold C, Lehrnbecher T, Klingspor L, Warris A, Leckerman K, Martling T, Walsh TJ, Benjamin DK, Jr, Zaoutis TE, International Pediatric Fungal Network. 2012. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 31:1252-1257. http://dx.doi.org/10 .1097/INF.0b013e3182737427.
36. Wade KC, Benjamin DK, Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, Gastonguay MR, Barrett JS. 2009. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 28:717-723. http://dx.doi.org/10.1097 /INF.0b013e31819f1f50.
37. U.S. Department of Health and Human Services. 2000. AIDSinfo: guidelines for the use of antiretroviral agents in pediatric HIV infection. U.S. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf
38. World Health Organization. 2010. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach, 2010 revision. HIV/AIDS Programme, World Health Organization, Geneva, Switzerland. http://apps.who.int /medicinedocs/documents/s18809en/s18809en.pdf.
39. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESMID Fungal Infection Study Group. 2012. ESCMID∗guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):S19-S37.
40. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox M. 2013. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (4):CD003543. http://dx.doi.org/10.1002/14651858.CD003543.pub3.
41. Ruhnke M. 2014. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 20(Suppl 6):S11-S18. http://dx.doi.org/10.1111 /1469-0691.12622.
42. Caliz B. 2014. Efficiency of an antifungal stewardship program (PROMULGA Project). Eur J Hosp Pharm 21: A210 -A211. http://dx .doi.org/10.1136/ejhpharm-2013-000436.515.
43. Mondain V, Lieutier F, Dumas S, Gaudart A, Fosse T, Roger PM, Bernard E, Farhad R, Pulcini C. 2013. An antibiotic stewardship program in a French teaching hospital. Med Mal Infect 43:17-21. http://dx .doi.org/10.1016/j.medmal.2012.10.006.
44. Valerio M, Rodriguez-Gonzalez CG, Muñoz P, Caliz B, Sanjurjo M, Bouza E, COMIC Study Group (Collaborative Group on Mycoses). 2014. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 69:1993-1999. http://dx.doi.org/10.1093/jac/dku053.
45. Hyun DY, Hersh AL, Namtu K, Palazzi DL, Maples HD, Newland JG, Saiman L. 2013. Antimicrobial stewardship in pediatrics: how every pediatrician can be a steward. JAMA Pediatr 167:859-866. http://dx.doi.org /10.1001/jamapediatrics.2013.2241.
46. Agwu AL, Lee CK, Jain SK, Murray KL, Topolski J, Miller RE, Townsend T, Lehmann CU. 2008. A World Wide Web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 47:747-753. http://dx.doi.org/10.1086/591133.
47. Aston J, Nusgen U. 2012. Antimicrobial stewardship in a tertiary paediatric hospital. Arch Dis Child 97:e2. http://dx.doi.org/10.1136/archdischi ld-2012-301728.4.